How the cutting-edge early phase oncology trials programme, START Dublin, came about and what it strives...

In this issue, highlights from the American Society of Clinical Oncology and European Haematology Association Annual...

Studies presented at the ESMO Gastrointestinal Cancers Congress 2024 could improve outcomes through better patient selection...

Neoadjuvant immunotherapy given for stage III melanoma, followed by adjuvant therapy only if there is not...

Osimertinib improves PFS in patients with unresectable stage III EGFR-mutated non-small cell lung cancer (NSCLC)...

The antibody-drug conjugate trastuzumab deruxtecan delays cancer growth for women with hormone receptor-positive (HR+)...

According to a new study presented at the 2024 ASCO Annual Meeting, adding the antibody-drug conjugate...

For patients with locally advanced oesophageal adenocarcinoma that can be treated with surgery, chemotherapy treatment...

Results from a new study presented at the 2024 American Society of Clinical Oncology (ASCO) Annual...

The management of bladder cancer is evolving rapidly, with a new regimen recently approved for patients...

RCSI research has found that venetoclax, a medication currently approved for leukaemia, has benefits for patients...

Testing for tumour DNA in the blood can successfully identify advanced bladder cancer patients who will...